Documentos relacionados

1. Análisis de impacto presupuestal de everolimus más ciclosporina y prednisona comparado con micofenolato más ciclosporina y prednisona para la profilaxis del rechazo en los receptores de trasplante de riñón en Colombia
2. Análisis de impacto presupuestal de everolimus más ciclosporina y prednisona comparado con micofenolato más ciclosporina y prednisona para la profilaxis del rechazo en los receptores de trasplante de corazón en Colombia
3. Everolimus versus mycophenolate mofetil in liver transplantation: every improvement in renal function matters.
4. An open-label randomized clinical trial to evaluate the efficacy of everolimus versus tacrolimus in triple maintenance immunosuppressive therapy for kidney transplant patients.
5. Viral-specific cytotoxic T-cell responses in HLA-sensitized kidney transplant patients maintained on everolimus and low-dose tacrolimus.
6. Adequacy of Initial Everolimus Dose, With and Without Calcineurin Inhibitors, in Kidney Transplant Recipients.
7. Evaluation of factors influencing the ratio of the trough blood concentration to dose level of everolimus in Japanese kidney transplant recipients.
8. Addendum to Jeng L-B, et al. Efficacy and safety of everolimus with reduced tacrolimus in living-donor liver transplant recipients: 12-month results of a randomized multicenter study. Am J Transplant. 2018;18:1435-1446.
9. Safety and Efficacy of Everolimus Rescue Treatment After Pediatric Living Donor Liver Transplantation.
10. Everolimus-facilitated calcineurin inhibitor reduction in Asian de novo kidney transplant recipients: 2-year results from the subgroup analysis of the TRANSFORM study.